文献速递类风湿关节炎

类风湿关节炎治疗药物关键临床试验中的安全性总体特征

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

结果显示总AE和SAE在药物间总体相当,但细化到特定器官分类和AESI时可见化合物及药物类别间的差异,标准化安全性特征有助于个体化选药和新型疗法早期安全性评估。

要点

  • 总AE和SAE的荟萃比较显示各药物总体安全性和耐受性相当。
  • 细化至器官分类和AESI可见化合物及药物类别间的安全性差异。

核心结论

  • 标准化安全性报告和特征分析可概览常用RA疗法的安全性结局,支持个体化安全导向选药。
  • 该特征为长期安全性数据尚未可及的新疗法安全性评估提供重要背景。

研究设计与样本

  • 系统检索EMBASE、Medline和Cochrane Library中bDMARDs和tsDMARDs的随机对照RA药物批准试验。
  • 应用MedDRA层级系统处理试验间异质性安全性报告,在较低MedDRA层级及主要系统器官分类层面进行随机效应荟萃分析。
  • SAE和AESI采用描述性研究,使用森林图和雷达图可视化生成各化合物的安全性特征。

主要发现

  • 总AE和SAE的荟萃层面比较显示总体安全性和耐受性相当。
  • 更细化的器官分类和AESI分析揭示了化合物及药物类别间的差异。

临床怎么用

  • 标准化安全性特征可支持个体患者中安全导向的治疗选择。
  • 该特征为新型疗法在长期安全性数据可及之前的安全性评估提供必要背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide a meta-level comparison of standardized safety profiles ('gestalt') of currently licensed biologic and targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) in rheumatoid arthritis (RA) from pivotal clinical trials. METHODS: We systematically searched EMBASE, Medline and the Cochrane Library for randomized controlled RA drug approval trials of bDMARDs and tsDMARDs. The Medical Dictionary for Regulatory Activities (MedDRA) hierarchy system was applied to account for the heterogeneous safety reporting across trials, and random-effects meta-analyses of adverse events (AE) were performed at lower MedDRA levels as well as for major system organ classes. Serious AEs (SAE) and AEs of special interest (AESI) were studied descriptively. Forest plots and radar charts were used for visualization, to generate distinct safety profiles, referred to as 'safety gestalt', for each compound. RESULTS: Sixty-four randomized, placebo-controlled drug approval trials were considered, of which 25 studied TNF-α inhibitors, 10 studied IL-6 receptor inhibitors, 5 studied rituximab, 7 studied abatacept and 18 studied Janus kinase inhibitors. Meta-level comparisons of the total number of AEs and SAEs showed comparable overall safety and tolerability, while a more granular insight into distinct organ classes and AESIs disentailed differences between compounds and drug classes. CONCLUSION: Standardized safety reporting and profiling of bDMARDs and tsDMARDs from pivotal clinical drug trials provides an overview of safety outcomes of commonly used RA therapies, supports safety-oriented treatment selection in individual patients, and provides essential context for safety evaluation of novel therapies during periods before long-term safety data become available.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Konzett V, Kerschbaumer A, Willmann L, et al. Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials. Rheumatology (Oxford). 2026. PMID: 42360790. doi:10.1093/rheumatology/keag263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。